No Evidence of Rapid Antiviral Clearance or Clinical Benefit With the Combination of Hydroxychloroquine and Azithromycin in Patients With Severe COVID-19 Infection

Med Mal Infect. 2020 Jun;50(4):384. doi: 10.1016/j.medmal.2020.03.006. Epub 2020 Mar 30.

Publication types

  • Clinical Trial
  • Letter

MeSH terms

  • Adult
  • Aged
  • Antiviral Agents / therapeutic use
  • Azithromycin / therapeutic use*
  • Betacoronavirus / isolation & purification
  • Coronavirus Infections / therapy*
  • Drug Therapy, Combination / standards
  • Female
  • Humans
  • Hydroxychloroquine / therapeutic use*
  • Male
  • Middle Aged
  • Pandemics
  • Pneumonia, Viral / therapy*
  • Treatment Outcome
  • Young Adult

Substances

  • Antiviral Agents
  • Hydroxychloroquine
  • Azithromycin

Supplementary concepts

  • COVID-19
  • severe acute respiratory syndrome coronavirus 2